Story perspectives

FDA Approves Spravato Nasal Spray for Depression Relief

2/25/2025

50 10

Summary

Story summary

The FDA has greenlit Spravato, an esketamine nasal spray, as a groundbreaking option for adults battling treatment-resistant depression. In clinical trials, 22.5% of participants found relief, though some experienced dizziness and elevated blood pressure. Due to its risks, this innovative treatment will only be administered in certified healthcare facilities, addressing a pressing need for the 8% of Americans grappling with major depressive disorder.

1 of 1

Story summary

The FDA has greenlit Spravato, an esketamine nasal spray, as a groundbreaking option for adults battling treatment-resistant depression. In clinical trials, 22.5% of participants found relief, though some experienced dizziness and elevated blood pressure. Due to its risks, this innovative treatment will only be administered in certified healthcare facilities, addressing a pressing need for the 8% of Americans grappling with major depressive disorder.